ArticleVox sanguinis2026
Hypoxic-hypocapnic red blood cells in PAGGSM additive solution before and after gamma irradiation show improved metabolism.
Article in Vox sanguinis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
BACKGROUND AND
objectivesHypoxic/hypocapnic (HH) treatment and storage conditions have been shown to reduce oxidative stress and improve red blood cell (RBC) quality. This study aimed to validate a good manufacturing practice HH RBC product for obtaining the licence for routine use in patients, by comparison with normoxic RBCs both without irradiation and after gamma irradiation. MATERIALS AND
methodsForty-four units of leucoreduced red cell concentrates (LR-RCCs) were prepared from 500 mL citrate-phosphate-dextrose (CPD)/phosphate-adenine-glucose-guanosine-saline-mannitol (PAGGSM) whole-blood donations. Paired units of ABO-matched LR-RCCs were pooled and split into equal aliquots. Twenty-two units (control) were maintained at room temperature for 3 h, while 22 units underwent HH treatment for 3 h using the Hemanext ONE® system. Eleven control and 11 HH LR-RCCs were assigned to the non-irradiated arm, and the remaining 22 units (11 control, 11 HH) were irradiated on Day 14. In vitro RBC quality was measured until Day 42 (non-irradiated) and Day 28 (irradiated on Day 14).
resultsThe HH product was comparable to controls in haemoglobin (Hgb) content, haematocrit, potassium and haemolysis, both without irradiation over 42 days and after irradiation over 28 days. HH RBCs contained 1.2-fold higher adenosine triphosphate (ATP) and up to 6.2-fold higher 2,3-diphosphoglycerate (2,3-DPG) levels. Lactate was 25% increased, and glucose levels were up to 30% decreased compared with normoxic RBCs.
conclusionHH storage enhanced RBC ATP and 2,3-DPG levels and yielded a product fulfilling RBC quality criteria for the other parameters. These findings support its clinical use for optimizing RBC transfusion quality, particularly for irradiated units.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.